Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced / metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinom

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.